Bundibugyo virus disease: Transmission dynamics, infectiousness and viral persistence - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Transmission Patterns, Infectiousness, and Viral Longevity in Bundibugyo Virus Disease

  • By

  • Andrea Bongiovanni

  • Erica Binetti

  • Francesca Colavita

  • Ilaria Mussetto

  • Laura Scorzolini

  • Eleonora Lalle

  • Andrea Antinori

  • Enrico Girardi

  • Fabrizio Maggi

  • Emanuele Nicastri

  • Francesco Vairo

  • September 1, 2026

Share

  • 1

    Bundibugyo virus disease (BVD) is a severe hemorrhagic fever caused by Bundibugyo virus (BDBV), first identified during Uganda’s 2007–2008 outbreak.

  • 2

    As of June 6, 2026, the ongoing outbreak in the Democratic Republic of the Congo had resulted in 515 laboratory-confirmed cases and 91 confirmed deaths, although these figures remained subject to change.

  • 3

    BDBV spreads primarily through direct contact with the blood or body fluids of symptomatic or deceased individuals, including within households, healthcare settings, and during burial activities.

  • 4

    No human cases of presymptomatic BDBV transmission have been documented, although animal-model evidence supports its biological plausibility.

  • 5

    No BDBV-specific evidence is available on post-recovery viral persistence or transmission from survivors; current recommendations rely largely on evidence involving Zaire ebolavirus.

Original Source(s)

Bundibugyo virus disease: Transmission dynamics, infectiousness and viral persistence

  • by Andrea Bongiovanni, Erica Binetti, Francesca Colavita, Ilaria Mussetto, Laura Scorzolini, Eleonora Lalle, Andrea Antinori, Enrico Girardi, Fabrizio Maggi, Emanuele Nicastri, Francesco Vairo

  • September 1, 2026

Related Content

Personify Group Names Michelle Strange to Advisory Board

Dental hygienist will contribute perspectives on infection prevention, clinical workflow and commercialization strategy.

Sepsis-associated liver injury: from liver-test risk signals to immunobiology-guided precision medicine

Pharmacometric analyses of various ivermectin dose regimens in Kenya to inform dosing in mass drug administration trials for malaria vector control